- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05753683
Gathering Online for Dialogue and Discussion to Enhance Social Support (GODDESS)
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging Young African American Women in a Virtual Group App to Address Alcohol Misuse, Sexual Risk, and Pre-exposure Prophylaxis (PrEP) in North Carolina (NC)
The goal of this trial is to test a modified mobile health intervention (with a group component) relative to a mobile health intervention in a two-arm randomized trial with 500 young African American women who are human immunodeficiency virus (HIV)-negative and who misuse alcohol.
The expected outcomes are to: (1) determine the efficacy of the virtual group component in reducing alcohol use and sexual risk and increasing pre-exposure prophylaxis (PrEP) utilization; and (2) understand selected outcomes for implementation.
Participants will be randomized to receive either the mHealth app or the mHealth app plus the group component, and followed up at 3-, 6-, 9-, and 12-months post-enrollment.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Felicia A Browne, ScD, MPH
- Phone Number: 9195416596
- Email: fbrowne@rti.org
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27707
- RTI International
-
Contact:
- Felicia A Browne, ScD, MPH
- Phone Number: 919-541-6596
- Email: fbrowne@rti.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Selected Inclusion Criteria:
- identify as Black/African American
- identify as female
- be between 18 and 30 years old
- recent substance use
- HIV negative and not currently on PrEP
- have an Android or iOS-based smartphone
Selected Exclusion Criteria:
- test positive for HIV
- participated in the previous study activities of the current study or previous related studies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard: mHealth-Women's CoOp
Participants assigned to receive an evidence-based mHealth alcohol and other drug use and sexual risk reduction intervention for young African American women.
The app will be installed on each participant's smartphone by study staff after randomization.
|
The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a gender-specific human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and gender-based violence through education, skills-building, and role-play and rehearsal via a mobile app.
The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period.
Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
|
Experimental: Enhanced: mHealth-Women's CoOp+Group
Participants assigned to receive an evidence-based mHealth alcohol and other drug use and sexual risk reduction intervention for young African American women, in addition to a virtual peer group component.
The app with a link to the virtual group will be installed on each participant's smartphone by study staff after randomization.
|
The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a gender-specific human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and gender-based violence through education, skills-building, and role-play and rehearsal via a mobile app.
The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period.
Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
The enhanced online group component will be available to be accessed using the mHealth-Women's CoOp platform for participants in the enhanced arm.
The purpose of this component is to allow for young women who use alcohol to interact with young women like them and also discuss issues related to substance use and sexual risk-taking via a guided conversation to allow for motivational and informational support.
The virtual group component will include online live discussions moderated and monitored by a trained online facilitator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alcohol (Biological)
Time Frame: Baseline
|
Recent alcohol (last 10 days) use will be measured by the presence of ethyl glucuronide (EtG), a breakdown product of ethanol, using an ethyl glucuronide (EtG) urine test.
The One Step Ethyl Glucuronide (EtG) Test Dip Card is a lateral flow chromatographic immunoassay.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Urine EtG ≥300 ng/mL indicates a positive result.
|
Baseline
|
Alcohol (Biological)
Time Frame: 3-month
|
Recent alcohol (last 10 days) use will be measured by the presence of ethyl glucuronide (EtG), a breakdown product of ethanol, using an ethyl glucuronide (EtG) urine test.
The One Step Ethyl Glucuronide (EtG) Test Dip Card is a lateral flow chromatographic immunoassay.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Urine EtG ≥300 ng/mL indicates a positive result.
|
3-month
|
Alcohol (Biological)
Time Frame: 6-month
|
Recent alcohol (last 10 days) use will be measured by the presence of ethyl glucuronide (EtG), a breakdown product of ethanol, using an ethyl glucuronide (EtG) urine test.
The One Step Ethyl Glucuronide (EtG) Test Dip Card is a lateral flow chromatographic immunoassay.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Urine EtG ≥300 ng/mL indicates a positive result.
|
6-month
|
Alcohol (Biological)
Time Frame: 9-month
|
Recent alcohol (last 10 days) use will be measured by the presence of ethyl glucuronide (EtG), a breakdown product of ethanol, using an ethyl glucuronide (EtG) urine test.
The One Step Ethyl Glucuronide (EtG) Test Dip Card is a lateral flow chromatographic immunoassay.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Urine EtG ≥300 ng/mL indicates a positive result.
|
9-month
|
Alcohol (Biological)
Time Frame: 12-month
|
Recent alcohol (last 10 days) use will be measured by the presence of ethyl glucuronide (EtG), a breakdown product of ethanol, using an ethyl glucuronide (EtG) urine test.
The One Step Ethyl Glucuronide (EtG) Test Dip Card is a lateral flow chromatographic immunoassay.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Urine EtG ≥300 ng/mL indicates a positive result.
|
12-month
|
Alcohol (Biological)
Time Frame: Baseline
|
Phosphatidylethanol (PEth) in dried blood spots (DBS) with concentration greater than 20 ng/mL is an indication of alcohol exposure in the last 2-4 weeks (approximately).
Higher concentrations of PEth indicates higher recent alcohol consumption.
|
Baseline
|
Alcohol (Biological)
Time Frame: 3-month
|
Phosphatidylethanol (PEth) in dried blood spots (DBS) with concentration greater than 20 ng/mL is an indication of alcohol exposure in the last 2-4 weeks (approximately).
Higher concentrations of PEth indicates higher recent alcohol consumption.
|
3-month
|
Alcohol (Biological)
Time Frame: 6-month
|
Phosphatidylethanol (PEth) in dried blood spots (DBS) with concentration greater than 20 ng/mL is an indication of alcohol exposure in the last 2-4 weeks (approximately).
Higher concentrations of PEth indicates higher recent alcohol consumption.
|
6-month
|
Alcohol (Biological)
Time Frame: 9-month
|
Phosphatidylethanol (PEth) in dried blood spots (DBS) with concentration greater than 20 ng/mL is an indication of alcohol exposure in the last 2-4 weeks (approximately).
Higher concentrations of PEth indicates higher recent alcohol consumption.
|
9-month
|
Alcohol (Biological)
Time Frame: 12-month
|
Phosphatidylethanol (PEth) in dried blood spots (DBS) with concentration greater than 20 ng/mL is an indication of alcohol exposure in the last 2-4 weeks (approximately).
Higher concentrations of PEth indicates higher recent alcohol consumption.
|
12-month
|
Alcohol (Self-Reported)
Time Frame: Baseline
|
Revised Risk Behavior Assessment (RRBA): Volume (grams of ethanol, accounting for different standard drink size), frequency of use, frequency of binge, heavy episodic drinking (4+ drinks/day).
|
Baseline
|
Alcohol (Self-Reported)
Time Frame: 3-month
|
Revised Risk Behavior Assessment (RRBA): Volume (grams of ethanol, accounting for different standard drink size), frequency of use, frequency of binge, heavy episodic drinking (4+ drinks/day).
|
3-month
|
Alcohol (Self-Reported)
Time Frame: 6-month
|
Revised Risk Behavior Assessment (RRBA): Volume (grams of ethanol, accounting for different standard drink size), frequency of use, frequency of binge, heavy episodic drinking (4+ drinks/day).
|
6-month
|
Alcohol (Self-Reported)
Time Frame: 9-month
|
Revised Risk Behavior Assessment (RRBA): Volume (grams of ethanol, accounting for different standard drink size), frequency of use, frequency of binge, heavy episodic drinking (4+ drinks/day).
|
9-month
|
Alcohol (Self-Reported)
Time Frame: 12-month
|
Revised Risk Behavior Assessment (RRBA): Volume (grams of ethanol, accounting for different standard drink size), frequency of use, frequency of binge, heavy episodic drinking (4+ drinks/day).
|
12-month
|
Alcohol (Self-Reported)
Time Frame: Baseline
|
World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for alcohol consumption problems via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for alcohol consumption problems.
Scores from 0 to 10 indicate lower risk for alcohol problems, scores from 11 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
Baseline
|
Alcohol (Self-Reported)
Time Frame: 3-month
|
World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for alcohol consumption problems via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for alcohol consumption problems.
Scores from 0 to 10 indicate lower risk for alcohol problems, scores from 11 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
3-month
|
Alcohol (Self-Reported)
Time Frame: 6-month
|
World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for alcohol consumption problems via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for alcohol consumption problems.
Scores from 0 to 10 indicate lower risk for alcohol problems, scores from 11 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
6-month
|
Alcohol (Self-Reported)
Time Frame: 9-month
|
World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for alcohol consumption problems via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for alcohol consumption problems.
Scores from 0 to 10 indicate lower risk for alcohol problems, scores from 11 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
9-month
|
Alcohol (Self-Reported)
Time Frame: 12-month
|
World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for alcohol consumption problems via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for alcohol consumption problems.
Scores from 0 to 10 indicate lower risk for alcohol problems, scores from 11 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
12-month
|
Sexual Risk: HIV (Biological)
Time Frame: Baseline
|
Number of participants living with HIV as assessed by OraQuick® ADVANCE Rapid HIV-1/2 Antibody Test with oral fluid, with an approximate 99.3% sensitivity & 99.8% specificity, which detects antibodies to HIV-1 and HIV-2.
|
Baseline
|
Sexual Risk: HIV (Biological)
Time Frame: 12-month
|
Number of participants living with HIV as assessed by OraQuick® ADVANCE Rapid HIV-1/2 Antibody Test with oral fluid, with an approximate 99.3% sensitivity & 99.8% specificity, which detects antibodies to HIV-1 and HIV-2.
|
12-month
|
Sexual Risk: Sexually Transmitted Infections (Biological)
Time Frame: Baseline
|
Number of participants testing positive for Chlamydia trachomatis as assessed by a polymerase chain reaction (PCR) test (Positive Percent Agreement [PPA]: 97.4%; Negative Percent Agreement [NPA]: 97.8%); number of participants testing positive for Neisseria Gonorrhoeae as assessed by a PCR test (PPA: 97.8%; NPA: 99.1%).
PCR testing will return a positive result when presence of the sexually transmitted infection's genetic code is detected.
Other possible results include negative or indeterminate.
|
Baseline
|
Sexual Risk: Sexually Transmitted Infections (Biological)
Time Frame: 3-month
|
Number of participants testing positive for Chlamydia trachomatis as assessed by a polymerase chain reaction (PCR) test (Positive Percent Agreement [PPA]: 97.4%; Negative Percent Agreement [NPA]: 97.8%); number of participants testing positive for Neisseria Gonorrhoeae as assessed by a PCR test (PPA: 97.8%; NPA: 99.1%).
PCR testing will return a positive result when presence of the sexually transmitted infection's genetic code is detected.
Other possible results include negative or indeterminate.
|
3-month
|
Sexual Risk: Sexually Transmitted Infections (Biological)
Time Frame: 6-month
|
Number of participants testing positive for Chlamydia trachomatis as assessed by a polymerase chain reaction (PCR) test (Positive Percent Agreement [PPA]: 97.4%; Negative Percent Agreement [NPA]: 97.8%); number of participants testing positive for Neisseria Gonorrhoeae as assessed by a PCR test (PPA: 97.8%; NPA: 99.1%).
PCR testing will return a positive result when presence of the sexually transmitted infection's genetic code is detected.
Other possible results include negative or indeterminate.
|
6-month
|
Sexual Risk: Sexually Transmitted Infections (Biological)
Time Frame: 9-month
|
Number of participants testing positive for Chlamydia trachomatis as assessed by a polymerase chain reaction (PCR) test (Positive Percent Agreement [PPA]: 97.4%; Negative Percent Agreement [NPA]: 97.8%); number of participants testing positive for Neisseria Gonorrhoeae as assessed by a PCR test (PPA: 97.8%; NPA: 99.1%).
PCR testing will return a positive result when presence of the sexually transmitted infection's genetic code is detected.
Other possible results include negative or indeterminate.
|
9-month
|
Sexual Risk: Sexually Transmitted Infections (Biological)
Time Frame: 12-month
|
Number of participants testing positive for Chlamydia trachomatis as assessed by a polymerase chain reaction (PCR) test (Positive Percent Agreement [PPA]: 97.4%; Negative Percent Agreement [NPA]: 97.8%); number of participants testing positive for Neisseria Gonorrhoeae as assessed by a PCR test (PPA: 97.8%; NPA: 99.1%).
PCR testing will return a positive result when presence of the sexually transmitted infection's genetic code is detected.
Other possible results include negative or indeterminate.
|
12-month
|
Sexual Risk (Self-reported)
Time Frame: Baseline
|
Revised Risk Behavior Assessment (RRBA): Condomless vaginal or anal sex, impaired sex (AOD use prior to or during sex), casual partners, sex trading, & concurrent partners (≥2 partners), other contraceptive use, & perception of risk, HIV, recent STIs
|
Baseline
|
Sexual Risk (Self-reported)
Time Frame: 3-month
|
Revised Risk Behavior Assessment (RRBA): Condomless vaginal or anal sex, impaired sex (AOD use prior to or during sex), casual partners, sex trading, & concurrent partners (≥2 partners), other contraceptive use, & perception of risk, HIV, recent STIs
|
3-month
|
Sexual Risk (Self-reported)
Time Frame: 6-month
|
Revised Risk Behavior Assessment (RRBA): Condomless vaginal or anal sex, impaired sex (AOD use prior to or during sex), casual partners, sex trading, & concurrent partners (≥2 partners), other contraceptive use, & perception of risk, HIV, recent STIs
|
6-month
|
Sexual Risk (Self-reported)
Time Frame: 9-month
|
Revised Risk Behavior Assessment (RRBA): Condomless vaginal or anal sex, impaired sex (AOD use prior to or during sex), casual partners, sex trading, & concurrent partners (≥2 partners), other contraceptive use, & perception of risk, HIV, recent STIs
|
9-month
|
Sexual Risk (Self-reported)
Time Frame: 12-month
|
Revised Risk Behavior Assessment (RRBA): Condomless vaginal or anal sex, impaired sex (AOD use prior to or during sex), casual partners, sex trading, & concurrent partners (≥2 partners), other contraceptive use, & perception of risk, HIV, recent STIs
|
12-month
|
PrEP Utilization (Biological)
Time Frame: 3-month
|
Dried blood spot (DBS) samples will be analyzed by quantification of drug concentrations by liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology using assays validated at the study laboratory.
|
3-month
|
PrEP Utilization (Biological)
Time Frame: 6-month
|
Dried blood spot (DBS) samples will be analyzed by quantification of drug concentrations by liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology using assays validated at the study laboratory.
|
6-month
|
PrEP Utilization (Biological)
Time Frame: 9-month
|
Dried blood spot (DBS) samples will be analyzed by quantification of drug concentrations by liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology using assays validated at the study laboratory.
|
9-month
|
PrEP Utilization (Biological)
Time Frame: 12-month
|
Dried blood spot (DBS) samples will be analyzed by quantification of drug concentrations by liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology using assays validated at the study laboratory.
|
12-month
|
PrEP Utilization (Self-Reported)
Time Frame: Baseline
|
Revised Risk Behavior Assessment (RRBA): Self-reported past 30-day use, missed doses, and patterns of use
|
Baseline
|
PrEP Utilization (Self-Reported)
Time Frame: 3-month
|
Revised Risk Behavior Assessment (RRBA): Self-reported past 30-day use, missed doses, and patterns of use
|
3-month
|
PrEP Utilization (Self-Reported)
Time Frame: 6-month
|
Revised Risk Behavior Assessment (RRBA): Self-reported past 30-day use, missed doses, and patterns of use
|
6-month
|
PrEP Utilization (Self-Reported)
Time Frame: 9-month
|
Revised Risk Behavior Assessment (RRBA): Self-reported past 30-day use, missed doses, and patterns of use
|
9-month
|
PrEP Utilization (Self-Reported)
Time Frame: 12-month
|
Revised Risk Behavior Assessment (RRBA): Self-reported past 30-day use, missed doses, and patterns of use
|
12-month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Use (Biological)
Time Frame: Baseline
|
Alere iScreen®DX Multi-Drugs of Abuse Dip Test (Toxicology/TDM) Rapid urine-based drug screen to detect metabolites of recent drug use (>99% correlation to gas chromatography at 95% confidence level) 10-panel-amphetamine, benzodiazepines, barbiturates, cocaine, opiates, methamphetamine, ecstasy, methadone, phencyclidine, and marijuana.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Concentrations at or above the following cutoff concentrations indicate a positive result for the following substances: amphetamine (1000 ng/mL), benzodiazepines (300 ng/mL), barbiturates (300 ng/mL), cocaine (300 ng/mL), opiates (300 ng/mL), methamphetamine (500 ng/mL), ecstasy (500 ng/mL), methadone (300 ng/mL), phencyclidine (25 ng/mL), marijuana (50 ng/mL).
|
Baseline
|
Drug Use (Biological)
Time Frame: 3-month
|
Alere iScreen®DX Multi-Drugs of Abuse Dip Test (Toxicology/TDM) Rapid urine-based drug screen to detect metabolites of recent drug use (>99% correlation to gas chromatography at 95% confidence level) 10-panel-amphetamine, benzodiazepines, barbiturates, cocaine, opiates, methamphetamine, ecstasy, methadone, phencyclidine, and marijuana.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Concentrations at or above the following cutoff concentrations indicate a positive result for the following substances: amphetamine (1000 ng/mL), benzodiazepines (300 ng/mL), barbiturates (300 ng/mL), cocaine (300 ng/mL), opiates (300 ng/mL), methamphetamine (500 ng/mL), ecstasy (500 ng/mL), methadone (300 ng/mL), phencyclidine (25 ng/mL), marijuana (50 ng/mL).
|
3-month
|
Drug Use (Biological)
Time Frame: 6-month
|
Alere iScreen®DX Multi-Drugs of Abuse Dip Test (Toxicology/TDM) Rapid urine-based drug screen to detect metabolites of recent drug use (>99% correlation to gas chromatography at 95% confidence level) 10-panel-amphetamine, benzodiazepines, barbiturates, cocaine, opiates, methamphetamine, ecstasy, methadone, phencyclidine, and marijuana.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Concentrations at or above the following cutoff concentrations indicate a positive result for the following substances: amphetamine (1000 ng/mL), benzodiazepines (300 ng/mL), barbiturates (300 ng/mL), cocaine (300 ng/mL), opiates (300 ng/mL), methamphetamine (500 ng/mL), ecstasy (500 ng/mL), methadone (300 ng/mL), phencyclidine (25 ng/mL), marijuana (50 ng/mL).
|
6-month
|
Drug Use (Biological)
Time Frame: 9-month
|
Alere iScreen®DX Multi-Drugs of Abuse Dip Test (Toxicology/TDM) Rapid urine-based drug screen to detect metabolites of recent drug use (>99% correlation to gas chromatography at 95% confidence level) 10-panel-amphetamine, benzodiazepines, barbiturates, cocaine, opiates, methamphetamine, ecstasy, methadone, phencyclidine, and marijuana.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Concentrations at or above the following cutoff concentrations indicate a positive result for the following substances: amphetamine (1000 ng/mL), benzodiazepines (300 ng/mL), barbiturates (300 ng/mL), cocaine (300 ng/mL), opiates (300 ng/mL), methamphetamine (500 ng/mL), ecstasy (500 ng/mL), methadone (300 ng/mL), phencyclidine (25 ng/mL), marijuana (50 ng/mL).
|
9-month
|
Drug Use (Biological)
Time Frame: 12-month
|
Alere iScreen®DX Multi-Drugs of Abuse Dip Test (Toxicology/TDM) Rapid urine-based drug screen to detect metabolites of recent drug use (>99% correlation to gas chromatography at 95% confidence level) 10-panel-amphetamine, benzodiazepines, barbiturates, cocaine, opiates, methamphetamine, ecstasy, methadone, phencyclidine, and marijuana.
Each test has a control line region to serve as a procedural control and a test line region; results with only a line in the control region and without a line in the test region are classified as positive.
Concentrations at or above the following cutoff concentrations indicate a positive result for the following substances: amphetamine (1000 ng/mL), benzodiazepines (300 ng/mL), barbiturates (300 ng/mL), cocaine (300 ng/mL), opiates (300 ng/mL), methamphetamine (500 ng/mL), ecstasy (500 ng/mL), methadone (300 ng/mL), phencyclidine (25 ng/mL), marijuana (50 ng/mL).
|
12-month
|
Drug Use (Self-Reported)
Time Frame: Baseline
|
The World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for problems with drugs-such as marijuana, cocaine, amphetamine, and opioids-via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for drug use problems.
Scores from 0 to 3 indicate lower risk for drug use problems, scores from 4 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
Baseline
|
Drug Use (Self-Reported)
Time Frame: 3-month
|
The World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for problems with drugs-such as marijuana, cocaine, amphetamine, and opioids-via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for drug use problems.
Scores from 0 to 3 indicate lower risk for drug use problems, scores from 4 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
3-month
|
Drug Use (Self-Reported)
Time Frame: 6-month
|
The World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for problems with drugs-such as marijuana, cocaine, amphetamine, and opioids-via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for drug use problems.
Scores from 0 to 3 indicate lower risk for drug use problems, scores from 4 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
6-month
|
Drug Use (Self-Reported)
Time Frame: 9-month
|
The World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for problems with drugs-such as marijuana, cocaine, amphetamine, and opioids-via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for drug use problems.
Scores from 0 to 3 indicate lower risk for drug use problems, scores from 4 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
9-month
|
Drug Use (Self-Reported)
Time Frame: 12-month
|
The World Health Organization's Alcohol, Smoking & Substance Use Involvement Scale (ASSIST) assesses risk for problems with drugs-such as marijuana, cocaine, amphetamine, and opioids-via 8 items.
Scores range from 0 to 39, and this score indicates level of risk for drug use problems.
Scores from 0 to 3 indicate lower risk for drug use problems, scores from 4 to 26 indicate moderate risk, and scores from 27 to 39 indicate high risk.
|
12-month
|
Perceived social support
Time Frame: Baseline
|
Multidimensional Scale of Perceived Social Support assesses perceived social support Multidimensional Scale of Perceived Social Support assesses perceived social support from family, friends, and others across a 12-item scale.
Each item uses a 7-point scale (1 = very strongly disagree, 7 = very strongly agree).
Items are summed and the total score is divided by the number of items.
Scores range from 0 to 7. Higher scores indicate higher levels of social support.
|
Baseline
|
Perceived social support
Time Frame: 3-month
|
Multidimensional Scale of Perceived Social Support assesses perceived social support from family, friends, and others across a 12-item scale.
Each item uses a 7-point scale (1 = very strongly disagree, 7 = very strongly agree).
Items are summed and the total score is divided by the number of items.
Scores range from 0 to 7. Higher scores indicate higher levels of social support.
|
3-month
|
Perceived social support
Time Frame: 6-month
|
Multidimensional Scale of Perceived Social Support assesses perceived social support from family, friends, and others across a 12-item scale.
Each item uses a 7-point scale (1 = very strongly disagree, 7 = very strongly agree).
Items are summed and the total score is divided by the number of items.
Scores range from 0 to 7. Higher scores indicate higher levels of social support.
|
6-month
|
Perceived social support
Time Frame: 9-month
|
Multidimensional Scale of Perceived Social Support assesses perceived social support from family, friends, and others across a 12-item scale.
Each item uses a 7-point scale (1 = very strongly disagree, 7 = very strongly agree).
Items are summed and the total score is divided by the number of items.
Scores range from 0 to 7. Higher scores indicate higher levels of social support.
|
9-month
|
Perceived social support
Time Frame: 12-month
|
Multidimensional Scale of Perceived Social Support assesses perceived social support from family, friends, and others across a 12-item scale.
Each item uses a 7-point scale (1 = very strongly disagree, 7 = very strongly agree).
Items are summed and the total score is divided by the number of items.
Scores range from 0 to 7. Higher scores indicate higher levels of social support.
|
12-month
|
Gender-based Violence
Time Frame: Baseline
|
World Health Organization (WHO) gender-based violence scale: Self-reported occurrence of emotional, physical, and sexual violence across a 13-item scale.
Each item uses a 3-point response scale (1 = one, 3 = many).
Items are summed, and scores range from 13 to 39. Higher scores indicate more frequent occurrences of gender-based violence.
|
Baseline
|
Gender-based Violence
Time Frame: 3-month
|
World Health Organization (WHO) gender-based violence scale: Self-reported occurrence of emotional, physical, and sexual violence across a 13-item scale.
Each item uses a 3-point response scale (1 = one, 3 = many).
Items are summed, and scores range from 13 to 39. Higher scores indicate more frequent occurrences of gender-based violence.
|
3-month
|
Gender-based Violence
Time Frame: 6-month
|
World Health Organization (WHO) gender-based violence scale: Self-reported occurrence of emotional, physical, and sexual violence across a 13-item scale.
Each item uses a 3-point response scale (1 = one, 3 = many).
Items are summed, and scores range from 13 to 39. Higher scores indicate more frequent occurrences of gender-based violence.
|
6-month
|
Gender-based Violence
Time Frame: 9-month
|
World Health Organization (WHO) gender-based violence scale: Self-reported occurrence of emotional, physical, and sexual violence across a 13-item scale.
Each item uses a 3-point response scale (1 = one, 3 = many).
Items are summed, and scores range from 13 to 39. Higher scores indicate more frequent occurrences of gender-based violence.
|
9-month
|
Gender-based Violence
Time Frame: 12-month
|
World Health Organization (WHO) gender-based violence scale: Self-reported occurrence of emotional, physical, and sexual violence across a 13-item scale.
Each item uses a 3-point response scale (1 = one, 3 = many).
Items are summed, and scores range from 13 to 39. Higher scores indicate more frequent occurrences of gender-based violence.
|
12-month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Felicia A Browne, ScD, MPH, RTI International
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0218271
- R01AA030452 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on mHealth-Women's CoOp
-
RTI InternationalDurham County Department of Public Health; Guilford County Department of Public... and other collaboratorsTerminatedHuman Immunodeficiency Virus (HIV) | Condomless Sex | Alcohol and Drug Use | Sexually Transmitted Infection (STI)United States
-
RTI InternationalNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Medical Research...Completed
-
RTI InternationalMedical Research Council, South AfricaCompletedHuman Immunodeficiency Virus (HIV) | Condomless Sex | Alcohol and Drug Use | Sexually Transmitted Infections (STIs) | Violence and Victimization | Access and Linkage to Healthcare | Education AdvancementSouth Africa
-
Brown UniversityNational Institute of Mental Health (NIMH)CompletedSexual Assault | Unsafe Sex | Physical Violence | Sexual AbuseUnited States
-
Eunice Kennedy Shriver National Institute of Child...Medical Research Council, South AfricaCompletedHIV | Substance Abuse | ViolenceSouth Africa
-
RTI InternationalKheth'ImpiloCompletedHIV | Substance AbuseUnited States, South Africa
-
RTI InternationalSetshaba Research CentreCompletedHIV PreventionSouth Africa
-
RTI InternationalCenters for Disease Control and PreventionCompletedSexually Transmitted Diseases | HIV | Substance Abuse | Violence | Victimization | Sexual RiskUnited States
-
RTI InternationalMedical Research Council, South AfricaCompleted
-
RTI InternationalUniversity of North Carolina, Chapel HillCompletedSexually Transmitted Diseases | HIV | Substance Abuse | Violence | Victimization | Sexual RiskUnited States, South Africa